| Date | Title | | | 05/09/12 | Idera Pharmaceuticals Reports First Quarter 2012 Financial Results| CAMBRIDGE, Mass., May 09, 2012 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today reported financial
results for the quarter ended March 31, 2012.
"We are focusing our development effort on our autoimmune disease
program and have continued to advance our lead candidates, IMO-3100 and
IMO-8400. We initiated a Phase 2 study of IMO-3100 in patients with
psoriasis in the second quarter and expect to complete it during the
first half of 2013.... |
|  | | 05/07/12 | Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in
Preclinical Models of Lupus and Psoriasis| IMO-8400 is a Lead Candidate for Development in Lupus
CAMBRIDGE, Mass., May 07, 2012 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced data from
preclinical studies of IMO-8400, demonstrating a novel mechanism of
action that may be applicable to the treatment of systemic lupus
erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific
Toll-like receptors (TLRs). The data were presented at the American
Asso... |
| | | 05/03/12 | Idera Pharmaceuticals Announces Top-line Results from a Phase 2
Clinical Trial of IMO-2055 in Treatment of Patients with Advanced Head
and Neck Cancer| CAMBRIDGE, Mass., May 03, 2012 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced top-line
results of a randomized, controlled Phase 2 clinical trial of IMO-2055,
the Company's investigational oncology product candidate targeting
Toll-like Receptor 9 in combination with Erbitux(R) (cetuximab) for the
treatment of recurrent or metastatic squamous cell carcinoma of the head
and neck (SCCHN) in patients who previously progressed on c... |
| | | 05/01/12 | Idera Pharmaceuticals Announces Presentation of Preclinical Data of
IMO-8400 in Both Lupus and Psoriasis Models| Data to Be Presented at American Association of Immunologists Meeting
2012
CAMBRIDGE, Mass., May 01, 2012 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will
be presenting data from preclinical studies of its Toll-like receptor
(TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus
(SLE) and psoriasis, which suggest that IMO-8400 may be useful for the
treatment of both indications. The data fro... |
| |
|
